Novo Nordisk Gains Positive CHMP Opinion for FREHEMGO
BAGSVAERD, Denmark — September 17, 2026 Novo Nordisk announced that the Committee for Medicinal Products for Human Use (CHMP)...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
BAGSVAERD, Denmark — September 17, 2026 Novo Nordisk announced that the Committee for Medicinal Products for Human Use (CHMP)...
PLAINSBORO, N.J., and BAGSVÆRD, Denmark, June 26, 2026 Novo Nordisk announced it will present new clinical and scientific findings...
PLAINSBORO, N.J. & BAGSVAERD, Denmark, April 29, 2026 Novo Nordisk has announced that its investigational therapy denecimig (Mim8) significantly...
